Vectura Group (LON:VEC) was upgraded by analysts at Royal Bank of Canada to a “sector performer” rating in a research report issued on Thursday. The brokerage presently has a GBX 119 ($1.60) target price on the stock. Royal Bank of Canada’s target price points to a potential upside of 12.26% from the stock’s current price.
VEC has been the topic of a number of other reports. Panmure Gordon reiterated a “buy” rating on shares of Vectura Group in a report on Wednesday, August 30th. Citigroup dropped their target price on shares of Vectura Group from GBX 200 ($2.69) to GBX 180 ($2.42) and set a “buy” rating on the stock in a report on Monday, September 18th. Shore Capital reiterated a “buy” rating on shares of Vectura Group in a report on Thursday, November 9th. Peel Hunt reiterated a “hold” rating and issued a GBX 160 ($2.15) target price on shares of Vectura Group in a report on Wednesday, September 6th. Finally, Numis Securities reiterated a “buy” rating and issued a GBX 205 ($2.76) target price on shares of Vectura Group in a report on Thursday, October 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Vectura Group currently has an average rating of “Buy” and an average target price of GBX 177.89 ($2.39).
Vectura Group (LON VEC) traded down GBX 6 ($0.08) during midday trading on Thursday, hitting GBX 106 ($1.43). 9,559,388 shares of the company were exchanged, compared to its average volume of 2,470,000. Vectura Group has a twelve month low of GBX 86.50 ($1.16) and a twelve month high of GBX 166.97 ($2.25).
Vectura Group Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.